Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Lymphoplasmacytic Lymphoma: early-phase trial registry
1 of 6 indexed Recurrent Lymphoplasmacytic Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 1 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Recurrent Lymphoplasmacytic Lymphoma: 6 US clinical trials tracked, 1 recruiting.
Recurrent Lymphoplasmacytic Lymphoma is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is City of Hope Medical Center, running 2 of these trials.
Enrollment posture brief
Registry condition recurrent-lymphoplasmacytic-lymphoma
OPEN 1 | RECR 17% | LATE 0 | EARLY 6 | RANK #2866 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Renal Failure (17% recruiting · 6 trials)
Recurrent Lymphoplasmacytic Lymphoma lists 1 open slots (17% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Lymphoplasmacytic Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Lymphoplasmacytic Lymphoma is recruiting below its size-band peers.
1 of 6 indexed trials (16.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Lymphoplasmacytic Lymphoma research.
City of Hope Medical Center accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Lymphoplasmacytic Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 39 among the 6 trials that report a genuine target (sentinel values excluded). 6 of those (100%) plan for fewer than 100 participants.
-
Recurrent Lymphoplasmacytic Lymphoma research is mostly interventional.
6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Q702 for the Treatment of Patients With Hematologic Malignancies
Mayo Clinic
NCT06712810
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Fred Hutchinson Cancer Center
NCT03277729
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
NCT01955499
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
City of Hope Medical Center
NCT02153580
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
David Bond, MD
NCT03015896
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT03479268
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Lymphoplasmacytic Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Lymphoplasmacytic Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Lymphoplasmacytic Lymphoma page
6 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Recurrent Lymphoplasmacytic Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- City of Hope Medical Center sponsors the most Recurrent Lymphoplasmacytic Lymphoma trials on record, review their full trial history before evaluating a specific study. See City of Hope Medical Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Lymphoplasmacytic Lymphoma condition card totals 6 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.